Improve your knowledge in Genomic Oncology through this program, where you will find the best teaching material with real clinical cases. Learn here about the latest advances in the specialty to be able to perform a quality medical practice"

A fundamental objective of the program is to bring students closer to and disseminate informatics knowledge is already applied in other areas of knowledge, but has a minimal implementation in the medical world, despite the fact that for genomic medicine to become a reality, it is necessary to accurately interpret the huge volume of clinical information currently available and associate it with the biological data generated after a bioinformatics analysis. While this is a difficult challenge, it will allow the effects of genetic variation and potential therapies to be explored quickly, inexpensively and with greater precision than is currently possible.

Humans are not naturally equipped to perceive and interpret genomic sequences, to understand all the mechanisms, pathways and interactions that take place within a living cell, nor to make medical decisions with tens or hundreds of variables. To move forward, a system with superhuman analytical capabilities is required to simplify the work environment and show the relationships and proximities between variables. In genomics and biology, it is now recognized that it is better to spend resources on new computational techniques than on pure data collection, something that is possibly the same in medicine and, of course, oncology. 

We have millions of data or publications, but when they are analyzed by physicians or biologists, the conclusions are totally subjective and and relative to the available publications or data, which are prioritized arbitrarily. This generates partial knowledge, which is increasingly distanced from the genetic and biological knowledge available and supported by computation, so a giant step in the implementation of precision medicine is to reduce this distance through the massive analysis of available medical and pharmacological information.

Update your knowledge through the program in Genomic Oncology”

This Postgraduate certificate in Genomic Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Case studies presented by experts in Genomic Oncology Its graphic, schematic and eminently practical contents provide scientific and practical training in those disciplines that are essential for professional practice
• Developments on Genomic Oncology
• It contains practical exercises where the self-assessment process can be carried out to improve learning
• Special emphasis on innovative methodologies in Genomic Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Postgraduate certificate may be the best investment you can make in the selection of a refresher program for two reasons: in addition to updating your knowledge in Genomic Oncology, you will obtain a qualification from TECH Global University"

The teaching staff includes professionals from the field of Genomic Oncology who bring their experience to this program, as well as renowned specialists belonging to leading societies and prestigious universities.

Thanks to its multimedia content elaborated with the latest educational technology, this program will allow the professional a situated and contextual learning, that is to say, a simulated environment that will provide an immersive learning programmed to work in real situations.

This program is designed around Problem-Based Learning, whereby the students must try to solve the different professional practice situations that arise throughout the program. For this purpose, students will be assisted by an innovative, interactive video system created by renowned and experienced experts in the field of Genomic Oncology with extensive teaching experience.

Increase your confidence in decision making by updating your knowledge through this program"

Take the opportunity to learn about the latest advances in Genomic Oncology and improve the care of your patients"

The structure of the contents has been designed by a team of professionals from the best educational centers, universities, and companies in the national territory, aware of the relevance of current specialization in order to intervene in the training and support of students, and committed to quality teaching through New Educational Technologies.

This Postgraduate certificate in Genomic Oncology contains the most complete and up-to-date scientific program on the market”

Module 1. Genomic or Precision Oncology

1.1. Usefulness of Gene Expression Profiling in Cancer
1.2. Molecular Subtypes of Breast Cancer
1.3. Prognostic-Predictive Genomic Platforms in Breast Cancer
1.4. Therapeutic Targets in Non-Small Cell Lung Cancer

1.4.1. Introduction
1.4.2. Molecular Detection Techniques
1.4.3. EGFR Mutation
1.4.4. ALK Translocation
1.4.5. ROS Translocation
1.4.6. BRAF Mutation
1.4.7. NRTK Rearrangements
1.4.8. HER2 Mutation
1.4.9. MET Mutation/Amplification
1.4.10. RET Rearrangements
1.4.11. Other Molecular Targets

1.5. Molecular Classification of Colon Cancer
1.6. Molecular Studies in Gastric Cancer

1.6.1. Treatment of Advanced Gastric Cancer
1.6.2. HER2 Overexpression in Advanced Gastric Cancer
1.6.3. Identification and Interpretation of HER2 Overexpression in Advanced Gastric Cancer
1.6.4. Drugs With Activity Against HER2
1.6.5. Trastuzumab in the First Line of Advanced Gastric Cancer

1.6.5.1. Treatment of HER2+ Advanced Gastric Cancer After Progression to Trastuzumab-Based Regimens

1.6.6. Activity of Other Anti-HER2 Drugs in Advanced Gastric Cancer

1.7. GIST as a Model of Translational Research: 15 Years of Experience

1.7.1. Introduction
1.7.2. Mutations of KIT and PDGFRA as Major Promoters in GIST
1.7.3. Genotype in GIST: Prognostic and Predictive Value
1.7.4. Genotype in GIST and Resistance to imatinib
1.7.5. Conclusions

1.8. Molecular and Genomic Biomarkers in Melanoma
1.9. Molecular Classification of Brain Tumors
1.10. Molecular and Genomic Biomarkers in Melanoma
1.11. Immunotherapy and Biomarkers

1.11.1. Landscape of Immunological Therapies in Cancer Treatment and the Need to Define the Mutational Profile of a Tumor
1.11.2. Checkpoint Inhibitor Biomarkers: PD-L1 and Beyond

1.11.2.1. The Role of PD-L1 in Immune Regulation
1.11.2.2. Clinical Trial Data and PD-L1 Biomarker
1.11.2.3. Thresholds and Assays for PD-L1 Expression: A Complex Picture
1.11.2.4. Budding Biomarkers

1.11.2.4.1. Tumor Mutational Burden (TMB)

1.11.2.4.1.1. Quantification of the Tumor Mutational Burden
1.11.2.4.1.2. Evidence of the Tumor Mutational Burden
1.11.2.4.1.3. Burden as a Predictive Biomarker
1.11.2.4.1.4. Burden as a Prognosis Biomarker
1.11.2.4.1.5. The Future of the Mutational Burden

1.11.2.4.2. Microsatellite Instability
1.11.2.4.3. Immune Infiltrate Analysis
1.11.2.4.4. Toxicity Markers

1.11.2.5. Immune Checkpoint Drug Development in Cancer
1.11.2.6. Available Drugs

Module 2. Changes in Current Clinical Practice and New Applications with Genomic Oncology

2.1. Liquid Biopsies: Fashion or Future? 

2.1.1. Introduction
2.1.2. Circulating Tumor Cells
2.1.3. CtDNA
2.1.4. Clinical Applications
2.1.5. CtDNA Limitations
2.1.6. Conclusions and Future

2.2. Role of the Biobank in Clinical Research

2.2.1. Introduction
2.2.2. Is it Worth the Effort to Create a Biobank? 
2.2.3. How to Begin Establishing a Biobank
2.2.4. Informed Consent for the Biobank
2.2.5. Collecting Samples for the Biobank
2.2.6. Quality Control
2.2.7. Access to Samples

2.3. Clinical trials: New Concepts Based on Precision Medicine

2.3.1. What Are Clinical Trials? What Sets Them Apart From Other Types of Research? 

2.3.1.1. Types of Clinical Trials

2.3.1.1.1. By Their Objectives
2.3.1.1.2. By The Number of Participating Centers
2.3.1.1.3. By Their Methodology
2.3.1.1.4. By Their Level of Masking

2.3.2. Results of Clinical Trials in Thoracic Oncology

2.3.2.1. Related to Survival Time
2.3.2.2. Results Related to the Tumor
2.3.2.3. Results Notified by the Patient

2.3.3. Clinical Trials in the New Age of Precision Medicine

2.3.3.1. Precision Medicine
2.3.3.2. Terminology Relate to the Design of Trials in the Era of Precision Medicine

2.4. Incorporation of Actionable Markers in Clinical Practice
2.5. Application of Genomics in Clinical Practice by Type of Tumor
2.6. Decision Support Systems in Oncology Based on Artificial Intelligence

A unique, key and decisive program to boost your professional development”